Effect of ginsenoside Rb1 in ameliorating insulin resistance and ectopic fat deposition in obese mice induced by high fat diet

Zhongguo Zhongyao Zazhi

Volumn 38, Issue 23, 2013, Pages 4119-4123

  Shang, Wen Bin ^a   Yu, Xi Zhong ^a   Wang, Guo Qiang ^a   Zhao, Juan ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Ginsenoside Rb1; Insulin resistance; Liver fat deposition; Perilipin

Indexed keywords

FATTY ACID; GINSENOSIDE RB 1; GLUCOSE; HORMONE SENSITIVE LIPASE; INSULIN; PHOSPHODIESTERASE III; ROSIGLITAZONE; TRIACYLGLYCEROL; GINSENOSIDE;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; IN VITRO STUDY; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; MALE; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; BLOOD; BODY WEIGHT; C57BL MOUSE; DOSE RESPONSE; GENE EXPRESSION REGULATION; LIVER; METABOLISM; ORGAN SIZE; PATHOLOGY;

ADIPOSE TISSUE; ANIMALS; BODY WEIGHT; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; GENE EXPRESSION REGULATION; GINSENOSIDES; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MICE, INBRED C57BL; OBESITY; ORGAN SIZE; TRIGLYCERIDES;

EID: 84892950177     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20132326     Document Type: Article

References (11)

1. 2007, 27(2): 115.
2. 1 promotes adipogenesis in 3T3-L1 cells by enhancing PPARgamma2 and C/EBPalpha gene expression[J]. Life Sci, 2007, 80(7): 618.
3. 2007, 23(3): 258.
4. 1 stimulates glucose uptake through insulin-like signaling pathway in 3T3-L1 adipocytes[J]. J Endocrinol, 2008, 198(3): 561.
5. Salmon D M, J P Flatt. Effect of dietary fat content on the incidence of obesity among ad libitum fed mice[J]. Int J Obes, 1985, 9(6): 443.
6. Bays H, L Mandarino, R A DeFronzo. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach[J]. J Clin Endocrinol Metab, 2004, 89(2): 463.
7. Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome[J]. Pharmacol Res, 2006, 53(6): 482.
8. den Boer M, P J Voshol, F Kuipers, et al. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models[J]. Arterioscler Thromb Vasc Biol, 2004, 24(4): 644.
9. Duncan R E, M Ahmadian, K Jaworski, et al. Regulation of lipolysis in adipocytes[J]. Annu Rev Nutr, 2007, 27: 79.
10. Item F, D Konrad. Visceral fat and metabolic inflammation: the portal theory revisited[J]. Obes Rev, 2012, 13(Suppl 2): 30.
11. Kim H J, T W Jung, E S Kang, et al. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model[J]. Metabolism, 2007, 56(5): 676.